Myovant Sciences Ltd (MYOV):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Myovant Sciences Ltd (MYOV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8170
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Myovant Sciences Ltd (Myovant), a subsidiary of Roivant Sciences Ltd, is a biopharmaceutical company that develops and commercializes new treatments for women’s diseases and endocrine disorders. The company’s products include relugolix, an oral small molecule that functions as a gonadotropin-releasing hormone receptor antagonist targeting conditions such as heavy menstrual bleeding associated with uterine fibroids and others. It also offers MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation in assisted reproduction. The company has operations in the US, Ireland and Switzerland. Myovant is headquartered in London, the UK.

Myovant Sciences Ltd (MYOV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Myovant Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
Myovant Sciences Raises USD100 Million in Financing of Shares and Notes 10
Partnerships 12
Myovant Sciences Enters into Agreement with Flo Health 12
Myovant Sciences Enters into Option Agreement with Roivant Sciences 13
Licensing Agreements 14
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 14
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 15
Equity Offering 16
Myovant Sciences Raises USD75 Million in Public Offering of Shares 16
Myovant Sciences Raises USD22.5 Million in Private Placement of Shares 18
Myovant Sciences Plans to Raise up to USD300 Million in Public Offering of shares 19
Myovant Sciences Completes IPO for USD217.5 Million 20
Myovant Sciences Ltd – Key Competitors 22
Myovant Sciences Ltd – Key Employees 23
Myovant Sciences Ltd – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Aug 07, 2018: Myovant Sciences reports financial results for first fiscal quarter ended June 30, 2018 25
Jun 07, 2018: Myovant Provides Corporate Update and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2018 26
Feb 13, 2018: Myovant Sciences Provides Corporate Update and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2017 28
Nov 13, 2017: Myovant Sciences Provides Corporate Update and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2017 30
Aug 10, 2017: Myovant Sciences Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2017 32
Corporate Communications 34
Jul 19, 2017: Myovant Bolsters Executive Team with Key Management Appointments 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Myovant Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Myovant Sciences Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Myovant Sciences Raises USD100 Million in Financing of Shares and Notes 10
Myovant Sciences Enters into Agreement with Flo Health 12
Myovant Sciences Enters into Option Agreement with Roivant Sciences 13
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 14
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 15
Myovant Sciences Raises USD75 Million in Public Offering of Shares 16
Myovant Sciences Raises USD22.5 Million in Private Placement of Shares 18
Myovant Sciences Plans to Raise up to USD300 Million in Public Offering of shares 19
Myovant Sciences Completes IPO for USD217.5 Million 20
Myovant Sciences Ltd, Key Competitors 22
Myovant Sciences Ltd, Key Employees 23
Myovant Sciences Ltd, Subsidiaries 24

List of Figures
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Myovant Sciences Ltd (MYOV):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cara Therapeutics Inc (CARA):製薬・医療:M&Aディール及び事業提携情報
    Summary Cara Therapeutics Inc (Cara Therapeutics) is a biotechnology company that develops and commercializes chemical entities for acutepain, chronic pain and pruritus. The company offers kappa opioid receptor agonists in the therapeutic areas of acute pain, chronic pain, neuropathic pain and pruri …
  • Globeimmune Inc (GBIM):企業の財務・戦略的SWOT分析
    Summary Globeimmune Inc (Globeimmune) is a biopharmaceutical company that develops therapeutic products for treatment of cancer and infectious diseases. The company provides products for infectious disease and oncology. It offers oncology products such as GI-4000, GI-6207 and GI-6301. Globeimmune pr …
  • Bank of America Corp:企業の戦略・SWOT・財務分析
    Bank of America Corp - Strategy, SWOT and Corporate Finance Report Summary Bank of America Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Daihachi Chemical Industry Co Ltd:企業の戦略的SWOT分析
    Daihachi Chemical Industry Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Sonic Healthcare Ltd (SHL)-医療機器分野:企業M&A・提携分析
    Summary Sonic Healthcare Ltd (Sonic Healthcare) Sonic Healthcare is a medical diagnostics company that provides laboratory and diagnostic imaging services. The company provides laboratory medicine, pathology, radiology, diagnostic imaging and primary care medical services. It operates Australia's la …
  • Genetic Signatures Ltd (GSS):企業の製品パイプライン分析
    Summary Genetic Signatures Ltd (Genetic Signatures) formerly Human Genetic Signatures Pty Ltd, is a molecular diagnostics company. The company designs and manufactures real-time polymerase chain reaction (PCR) based products for the detection of infectious diseases under the EasyScreen brand. It off …
  • Nanosonics Ltd (NAN):医療機器:M&Aディール及び事業提携情報
    Summary Nanosonics Ltd (Nanosonics) is a medical technology company, which focuses on the development of technologies for infection control. Its product portfolio includes decontamination products and accessories for the prevention of hospital acquired infections (HAI). The company’s trophon EPR is …
  • Grifols SA (GRF):製薬・医療:M&Aディール及び事業提携情報
    Summary Grifols SA (Grifols) focuses at improving the health and well-being of people around the world. It carries out the research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. The company specializes in …
  • Kazanci Holding AS:電力:M&Aディール及び事業提携情報
    Summary Kazanci Holding AS (Kazanci) is an investment holding company. The company operates in the business of power generation, natural gas distribution, energy generation and electricity distribution and sales. It operates through business segments such as Aksa Energy, Aksa Electricity, Aksa Power …
  • Macro Enterprises Inc (MCR):企業の財務・戦略的SWOT分析
    Summary Macro Enterprises Inc (Macro Enterprises) is an oil and gas company that offers pipeline and facility construction and maintenance services. The company provides gathering, processing, transmission, storage and distribution of pipeline systems. It offers fabrication and installation of pipin …
  • Finder Exploration Pty Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Finder Exploration Pty Ltd (Finder) is an oil and gas company that acquires and explores prospective acreage. The company offers acquisition of prospective acreage through drilling and detailed assessment and risk mitigation of exploration acreage. It holds exploration operations in Bedout S …
  • The Timken Company
    The Timken Company - Strategy, SWOT and Corporate Finance Report Summary The Timken Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Crown Bioscience Inc (6554):製薬・医療:M&Aディール及び事業提携情報
    Summary Crown Bioscience Inc (Crown Bioscience) is a drug discovery company that provides drug discovery and development services. The company offers antibodies, proteins, cell lines, tumor samples, in vivo and in vitro research reagents. It offers services such as preclinical research services, onc …
  • Cytori Therapeutics Inc (CYTX)-医療機器分野:企業M&A・提携分析
    Summary Cytori Therapeutics Inc (Cytori) is a clinical stage regenerative medicine company. It develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) for the treatment of cardiovascular disease, orthopedic conditions and gastrointestinal disorders. The company has two …
  • Thomas Cook (India) Limited:企業の戦略・SWOT・財務分析
    Thomas Cook (India) Limited - Strategy, SWOT and Corporate Finance Report Summary Thomas Cook (India) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Merit Medical Systems Inc (MMSI):企業の財務・戦略的SWOT分析
    Merit Medical Systems Inc (MMSI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • PDL Biopharma, Inc.:企業の戦略・SWOT・財務分析
    PDL Biopharma, Inc. - Strategy, SWOT and Corporate Finance Report Summary PDL Biopharma, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Alternatifbank A.S.
    Alternatifbank A.S. - Strategy, SWOT and Corporate Finance Report Summary Alternatifbank A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Trinity Biotech Plc (TRIB)-医療機器分野:企業M&A・提携分析
    Summary Trinity Biotech Plc (Trinity Biotech) is a medical equipment company which develops, acquires, manufactures and distributes diagnostic systems for clinical laboratory and point-of-care sectors. The company’s product portfolio encompasses diagnostic tests and instruments that are used to dete …
  • Superior Energy Services Inc (SPN):企業の財務・戦略的SWOT分析
    Superior Energy Services Inc (SPN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆